Shingles Vaccine Timing for MS Patient on Kesimpta
This patient should receive the recombinant zoster vaccine (Shingrix) now without interrupting Kesimpta therapy, as it is a non-live vaccine that can be safely administered during anti-CD20 treatment.
Vaccine Type Selection
The critical first decision is vaccine selection. Only the recombinant zoster vaccine (Shingrix) should be used—never the live-attenuated vaccine (Zostavax) 1. The Kesimpta FDA label explicitly states that live or live-attenuated vaccines should not be given during treatment and until the immune system is no longer weakened 1. Since this patient is already 6 months into therapy, the live vaccine is contraindicated.
Timing Considerations
Current Situation (Already on Therapy)
Since the patient has been on Kesimpta for 6 months, the ideal window for vaccination (before starting therapy) has passed. The FDA label recommends non-live vaccines be given at least 2 weeks before starting Kesimpta "whenever possible" 1. However, this is a preference for optimal immune response, not an absolute requirement.
For patients already on anti-CD20 therapy like ofatumumab, vaccination should proceed without delay:
Do not stop Kesimpta for vaccination. The rheumatology guidelines for rituximab (another anti-CD20 antibody) recommend continuing the medication for non-influenza vaccines, though they suggest timing vaccination when the next dose is due and holding the drug for 2 weeks afterward 2. However, this approach is less practical with monthly subcutaneous ofatumumab compared to infused rituximab.
Administer Shingrix as a 2-dose series (doses given 2-6 months apart) without interrupting the monthly Kesimpta schedule.
Expected Immune Response
Important caveat: Anti-CD20 therapies substantially reduce antibody responses to vaccines 3. The patient should understand that:
- Antibody response will likely be blunted or absent
- However, T-cell responses remain robust even with B-cell depletion 3
- Some protection is better than none, especially given the increased infection risk with immunosuppression
- Standard serologic testing may not demonstrate vaccine response, but this does not mean the vaccine provided no benefit
Practical Algorithm
- Confirm vaccine type: Shingrix (recombinant) only—verify with pharmacy
- Administer first dose now without stopping Kesimpta
- Continue monthly Kesimpta as scheduled
- Give second Shingrix dose 2-6 months after the first
- Monitor for injection site reactions (common with both medications)
- Do not attempt serologic testing to confirm response—it will likely be negative but does not reflect true protection
Safety Considerations
The recombinant zoster vaccine has been shown safe in immunosuppressed populations 4. While specific data in MS patients on ofatumumab is limited, the EULAR guidelines note that Shingrix "may replace the live-attenuated vaccine in patients with AIIRD" based on its non-live nature 4. No treatment interruption is needed for safety.
The key pitfall to avoid: Delaying vaccination indefinitely while waiting for an "optimal" time. The patient is already at increased infection risk on immunosuppression, and herpes zoster rates are elevated in MS patients 4. Vaccinate now rather than risk a preventable infection.